» Articles » PMID: 23688322

Inhibiting Interleukin-4 and Interleukin-13 in Difficult-to-control Asthma

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2013 May 22
PMID 23688322
Citations 15
Authors
Affiliations
Soon will be listed here.
Citing Articles

Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature.

Reale M, Licci G, Orlando P, Matucci A, Trabalzini F, Maggiore G Eur Arch Otorhinolaryngol. 2024; 281(10):5023-5031.

PMID: 38762844 DOI: 10.1007/s00405-024-08725-7.


Recent advances in the epithelial barrier theory.

Pat Y, Yazici D, DAvino P, Li M, Ardicli S, Ardicli O Int Immunol. 2024; 36(5):211-222.

PMID: 38227765 PMC: 10989673. DOI: 10.1093/intimm/dxae002.


Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.

Orlando P, Licci G, Kuitche D, Matucci A, Vultaggio A, Gallo O Eur Arch Otorhinolaryngol. 2023; 281(3):1317-1324.

PMID: 37910208 DOI: 10.1007/s00405-023-08309-x.


Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13.

Pelaia C, Pelaia G, Crimi C, Maglio A, Armentaro G, Calabrese C Vaccines (Basel). 2022; 10(6).

PMID: 35746582 PMC: 9229960. DOI: 10.3390/vaccines10060974.


Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets.

Pelaia C, Heffler E, Crimi C, Maglio A, Vatrella A, Pelaia G Front Pharmacol. 2022; 13:851940.

PMID: 35350765 PMC: 8957960. DOI: 10.3389/fphar.2022.851940.